Published in BMJ on March 04, 1995
Validity of urinary monoamine assay sales under the "spot baseline urinary neurotransmitter testing marketing model". Int J Nephrol Renovasc Dis (2011) 1.10
Pharmacological treatment of Parkinson's disease. Postgrad Med J (2000) 0.87
Subcutaneous apomorphine in late stage Parkinson's disease: a long term follow up. J Neurol Neurosurg Psychiatry (1998) 0.86
S[+] Apomorphine is a CNS penetrating activator of the Nrf2-ARE pathway with activity in mouse and patient fibroblast models of amyotrophic lateral sclerosis. Free Radic Biol Med (2013) 0.83
Gene therapy: a viable therapeutic strategy for Parkinson's disease? J Neurol (2010) 0.80
Gypenosides attenuate the development of L-DOPA-induced dyskinesia in 6-hydroxydopamine-lesioned rat model of Parkinson's disease. BMC Neurosci (2015) 0.78
Critical aspects of clinical trial design for novel cell and gene therapies. Parkinsons Dis (2011) 0.76
Parkinson's disease. Postgrad Med J (1997) 0.75
Diagnosis and treatment of Parkinson's disease. Anticholinergic drugs are not contraindicated after iridotomy. BMJ (1995) 0.75
The "on-off" phenomenon in Parkinson's disease. Relation to levodopa absorption and transport. N Engl J Med (1984) 2.71
"On-off" effects in patients with Parkinson's disease on chronic levodopa therapy. Lancet (1976) 2.54
Early combination therapy (bromocriptine and levodopa) does not prevent motor fluctuations in Parkinson's disease. Neurology (1993) 2.16
Young onset Parkinson's disease. Mov Disord (1987) 1.67
Neurosurgical horizons in Parkinson's disease. Neurology (1993) 1.62
Onset and end-of-dose levodopa-induced dyskinesias. Possible treatment by increasing the daily doses of levodopa. Arch Neurol (1978) 1.58
Lisuride, a dopamine agonist in the treatment of early Parkinson's disease. Neurology (1989) 1.55
Clozapine in the treatment of psychosis in Parkinson's disease. Neurology (1989) 1.45
Early development of levodopa-induced dyskinesias and response fluctuations in young-onset Parkinson's disease. Neurology (1991) 1.41
Effect of peripheral catechol-O-methyltransferase inhibition on the pharmacokinetics and pharmacodynamics of levodopa in parkinsonian patients. Neurology (1994) 1.30
Subcutaneous apomorphine in Parkinson's disease: response to chronic administration for up to five years. Mov Disord (1993) 1.30
Early combination of bromocriptine and levodopa in the treatment of Parkinson's disease: a 5-year follow-up. Neurology (1987) 1.17
Modification of central dopaminergic mechanisms by continuous levodopa therapy for advanced Parkinson's disease. Ann Neurol (1990) 1.13
Mood swings associated with the 'on-off' phenomenon in Parkinson's disease. Psychol Med (1987) 1.03
The spectrum of levodopa-related fluctuations in Parkinson's disease. Neurology (1993) 0.98
Dystonia in Parkinson's disease: clinical and pharmacological features. Ann Neurol (1988) 0.98
Cholinergic-dependent cognitive deficits in Parkinson's disease. Ann Neurol (1987) 0.96
Catechol-O-methyltransferase inhibitor tolcapone prolongs levodopa/carbidopa action in parkinsonian patients. Neurology (1993) 0.91
Protein redistribution diet restores motor function in patients with dopa-resistant "off" periods. Neurology (1988) 0.90
The Sydney Multicentre Study of Parkinson's disease: a report on the first 3 years. J Neurol Neurosurg Psychiatry (1989) 0.89
A randomised controlled study comparing bromocriptine to which levodopa was later added, with levodopa alone in previously untreated patients with Parkinson's disease: a five year follow up. J Neurol Neurosurg Psychiatry (1994) 0.87
Long-term bromocriptine treatment of de novo patients with Parkinson's disease. A seven-year follow-up. Acta Neurol Scand (1990) 0.85
Drug treatment of Parkinson's disease: is "polypharmacy" best? J Neurol Neurosurg Psychiatry (1994) 0.80
Parkinsonism--recognition and differential diagnosis. BMJ (1995) 1.45